29 apr: HVIDT I HVIDT - 20 COOL DESIGNKØB
05 maj: FORÅRS (MAVE) FORNEMMELSE - FEM FANTASTISKE OPSKRIFTER
04-05-2011 07:30:26

First Quarter of 2011: Dräger increases net sales and earnings

Drägerwerk AG & Co. KGaA /

First Quarter of 2011: Dräger increases net sales and earnings

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

  • Earnings after income taxes grew 24 percent year-on-year
  • Growth forecast confirmed
  • Stefan Dräger: "Capital structure increases strategic scope of action"

Lübeck - Drägerwerk AG & Co. KGaA's order intake, net sales and earnings increased in the first quarter of 2011. Order intake went up by 11.8 percent (net of currency effects) to EUR 553.6 million year-on-year. Net sales rose by 5.7 percent (net of currency effects) to EUR 500.3 million, with particularly positive developments in the Americas and Asia / Pacific regions. The safety division recorded 9.1 percent growth (net of currency effects), net sales in the medical divisions increased by 3.7 percent. "Given the good first quarter, we are confirming our 2011 growth forecast," said Stefan Dräger, CEO of Drägerwerk Verwaltungs AG.

EBIT margin rose to 8.5 percent

Dräger achieved total Group EBIT of EUR 42.6 million in the first quarter of 2011, an increase of 15.9 percent compared to the prior year's period. The EBIT margin rose from 7.9 percent to 8.5 percent. Higher net sales, favorable exchange rates and positive changes to the product mix contributed to the development. As planned, these amounts were partially used as increased expenses for research and development, marketing and sales as well as IT infrastructure. Earnings after income taxes rose by 24 percent to EUR 23.2 million year-on-year.

Equity ratio went up to 33.1 percent

Dräger Group's equity rose by EUR 11.2 million to EUR 647.8 million in the first three months of 2011, with the equity ratio increasing from 32.2 percent on December 31, 2010, to 33.1 percent. On March 31, 2010, prior to the capital increase, the equity ratio had been at 21.8 percent. "We have more strategic scope of action as our equity is increasing. For this reason, we are aiming to generate an equity ratio of at least 35 percent. We want to be ready for the next slump of the global economy," highlighted Stefan Dräger.

Outlook: Order intake is expected to grow as fast as the overall global economy

Dräger expects its order intake in fiscal year 2011 to grow at least at the pace of global economic growth (IMF April 2011 forecast: +4.4 percent). This is based on the assumption of a stabilizing economy in Europe, continued economic recovery in North America, sustained market growth in developing countries and stable exchange rates. Lifecycle Solutions and Infrastructure Projects in particular are likely to drive expected growth in the lower one-digit percentage range in the medical division and compensate for a possible slowdown in the equipment business. Dräger expects increases in net sales for the safety division in the medium one-digit percentage range. According to the Executive Board, net sales growth in the Group in 2011 is expected to be one to two percentage points down on order intake growth as net sales in 2010 benefited from above-average order intake in the fourth quarter of 2009. Based on planned increases in product development investments, the expansion of the sales organization and improvements to the Group-wide IT infrastructure, Dräger still expects a Group EBIT margin between 7.5 percent and 8.5 percent for fiscal year 2011 (2010: 8.9 percent). In the medium term, the Company aims at growing stronger than the market and achieving an EBIT margin of at least 10 percent.

Key figures for the first three months of 2011 (€ million)

  Q1 2011 Q1 2010 Change Net of currency effects
Order intake 553.6 488.2 +13.4% +11.8%

Medical division

357.1

323.6

+10.4%

+9.2%

Safety division

204.0

172.3

+18.4%

+16.1%

         
Net sales 500.3 465.9 +7.4% +5.7%

Medical division

321.6

306.3

+5.0%

+3.7%

Safety division

185.9

167.0

+11.3%

+9.1%

         
EBIT[1] 42.6 36.8 +15.9%  

Medical division

30.6

40.3

-24.1%

 

Safety division

21.6

12.7

+69.7%

 

         
EBIT margin 8.5% 7.9%    
Earnings after income taxes 23.2 18.7    
EPS[2] preferred share 1.22 1.38    
EPS[2] common share 1.20 1.36    

 

[1] EBIT = Earnings before interest and taxes
[2] EPS = Earnings per share (in €)

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

Contact

Corporate Communications:

Burkard Dillig

Phone: +49 451 882-2185

burkard.dillig@draeger.com

Investor Relations:

Vanina Hoffmann

Phone: +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1512151

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
25
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
17
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
16
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
06 dec
 
Baronen, du har længe haft Bitcoin siger du? Men har først nævnt det herinde 13/10-2017?   Tror du v..
15
07 dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
13
08 dec
 
Jeg har i mange år været meget tilfreds med Nordnet, men nu er den gamle mands tålmodighed godt nok ..
13

Aktier/tendens: SAS klar med endelige regnskabstal før handelsstart

12-12-2017 08:15:47
Luftfartsselskabet SAS offentliggjorde forud for børsåbningen tirsdag sit endelige regnskab for det skæve regnskabsår 2016/17, og selskabet kan derfor løbe med en del af opmærksomheden ved handelsstart.Det danske aktiemarked kan gå endnu en grøn dag i møde på det ledende eliteindeks, hvis den amerikanske grønne bølge forplanter sig på de europæiske markeder.Mandag fik C20 Cap-indekset en positiv s..

Genmab-rival suser frem på børsen efter nyt kræftstudie

11-12-2017 15:04:38
Genmab kan om flere år møde øget konkurrence for sit største aktiv, kræftmidlet Darzalex, da det amerikanske biotekselskab Bluebird ifølge flere storbanker har et særdeles lovende middel under udvikling.Bluebird har fremlagt gode data for kræftmidlet CAR-T fra et fase 1-studie på konferencen ASH i USA, hvor Genmab også deltager med en præsentation.Goldman Sachs vurderer, at CAR-T ser ud til at vær..

Mærsk bliver overhalet af kinesisk konkurrent på robothavn

11-12-2017 12:24:01
Mærsks APM Terminals var først på banen med en fuldautomatiseret containerhavn i stor skala, men nu er selskabet ved at blive overhalet på størrelsen.I Yangshan nær Shanghai er det kinesiske havneselskab SIPG gået i gang med at teste verdens største automatiserede containerterminal.Yangshan-terminalen får en indledende kapacitet på 4 mio. tyvefodscontainere (TEU) om året, hvilket er godt halvanden..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Investeringsdirektør: Aktiepriserne bør få alarmlamperne til at blinke
2
Genmab-rival suser frem på børsen efter nyt kræftstudie
3
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
4
TK Development tager markant nedskrivning og venter stort underskud
5
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 11:16:20
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB7 - 2017-12-12 11:16:20 - 2017-12-12 11:16:20 - 1 - Website: OKAY